financetom
Business
financetom
/
Business
/
Deals of the day-Mergers and acquisitions
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Deals of the day-Mergers and acquisitions
Jul 3, 2024 3:13 AM

July 3 (Reuters - The following bids, mergers,

acquisitions and disposals were reported by 0930 GMT on

Wednesday:

** Germany's cabinet blocked the planned sale of Volkswagen

subsidiary MAN Energy Solutions' gas turbine

division to a Chinese company, two government sources said.

** A joint venture between Trafigura and the Frontier Group

of Companies (FGC) has completed its acquisition of the Mountain

Creek power plant from a group of financial investors for an

undisclosed sum, Trafigura said in a press release.

** British drugmaker GSK bought partner CureVac out

of their alliance on influenza and COVID-19 vaccine development,

boosting its messenger RNA credentials and extending the German

biotech company's financial lifeline.

** U.S. asset management company Artisan Investments has

taken a 10.01% stake in the Dutch healthcare technology group

Philips, according to a regulatory filing published.

** Dublin-based video game services group Keywords Studios ( KYYWF )

has agreed to a bid worth 2.2 billion pounds ($2.8

billion) from European private equity firm EQT,

saying it saw significant growth opportunities under EQT's

ownership.

** Nippon Steel's ( NISTF ) vice chairman plans to return to

the United States next week again to discuss its proposed

acquisition of U.S. Steel, a company spokesperson said.

** Shari Redstone's National Amusements has reached a

preliminary deal to sell its controlling interest in Paramount

Global ( PARAA ) to David Ellison's Skydance Media, three sources

familiar with the matter told Reuters on Tuesday.

** Blackstone and MBK Partners said the U.S. private

equity firm is selling Japanese drugmaker Alinamin

Pharmaceutical to the North Asian buyout fund.

** Vista Outdoor ( VSTO ) confirmed on Tuesday it received

additional information from MNC Capital as part of the

investment firm's efforts to acquire the sporting and outdoor

goods maker.

(Compiled by Rajarshi Roy and Sneha S K in Bengaluru)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
BRIEF-Coastalsouth Bancshares Inc Files For IPO Of Up To 2.6 Million Common Stock
BRIEF-Coastalsouth Bancshares Inc Files For IPO Of Up To 2.6 Million Common Stock
Jun 24, 2025
June 24 (Reuters) - CoastalSouth Bancshares Inc ( COSO ) : * COASTALSOUTH BANCSHARES INC FILES FOR IPO OF UP TO 2.6 MILLION COMMON STOCK - SEC FILING * COASTALSOUTH BANCSHARES SAYS ANTICIPATES IPO PRICE OF COMMON STOCK WILL BE BETWEEN $21.50 AND $23.50 PER SHARE Source text: Further company coverage: ...
TELUS and TransUnion Launching Branded Call Display in Canada
TELUS and TransUnion Launching Branded Call Display in Canada
Jun 24, 2025
07:14 AM EDT, 06/24/2025 (MT Newswires) -- TransUnion said Tuesday it is partnering with TELUS ( TU ) to implement Branded Call Display (BCD), which enables businesses to showcase their identity on incoming calls to TELUS ( TU ) mobility subscribers. The service allows TELUS ( TU ) customers to show their business name, logo and reason for the call...
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Royalty Pharma to pay up to $2 billion to Revolution Medicines for cancer drug
Royalty Pharma to pay up to $2 billion to Revolution Medicines for cancer drug
Jun 24, 2025
June 24 (Reuters) - Royalty Pharma ( RPRX ) said on Tuesday will pay up to $2 billion to Revolution Medicines ( RVMD ) to support the companies' plans for global development and commercialization of the experimental cancer drug daraxonrasib. ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved